Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GPR119 | Q8TDV5 | 11/20 | 0.40 |
| ▸ | HTR1A | P08908 | 4/20 | 0.37 |
| ▸ | HTR7 | P34969 | 4/20 | 0.37 |
| ▸ | PTGS1 | P23219 | 1/20 | 0.36 |
| ▸ | PTGS2 | P35354 | 1/20 | 0.36 |
| ▸ | PGR | P06401 | 1/20 | 0.34 |
| ▸ | FSCN1 | Q16658 | 1/20 | 0.34 |
| ▸ | PIK3CD | O00329 | 1/20 | 0.34 |
| ▸ | PIK3CB | P42338 | 1/20 | 0.34 |
| ▸ | MTOR | P42345 | 1/20 | 0.34 |
| ▸ | PIK3CG | P48736 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29566629 | 1.00 | GPR119 (0.40) | GPR119HTR1AHTR7PTGS1PTGS2 | |
| SCHEMBL26811500 | 0.91 | GPR119 (0.38) | GPR119HTR1AHTR7PTGS1PTGS2 | |
| SCHEMBL24309861 | 0.90 | HTR1A (0.40) | GPR119HTR1AHTR7PIK3CDPIK3CB | |
| SCHEMBL29567228 | 0.90 | HTR1A (0.40) | GPR119HTR1AHTR7PIK3CDPIK3CB | |
| SCHEMBL29567219 | 0.87 | HTR7 (0.42) | HTR1AHTR7 | |
| SCHEMBL24309381 | 0.87 | HTR7 (0.42) | HTR1AHTR7 | |
| SCHEMBL29566810 | 0.86 | FGFR1 (0.40) | HTR1AHTR7 | |
| SCHEMBL24309919 | 0.86 | FGFR1 (0.40) | HTR1AHTR7 | |
| SCHEMBL24309827 | 0.86 | HTR1A (0.43) | HTR1AHTR7PIK3CDPIK3CBMTOR | |
| SCHEMBL29566900 | 0.86 | HTR1A (0.43) | HTR1AHTR7PIK3CDPIK3CBMTOR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230373935-A1 | MODULATORS OF CYSTIC FIBROSIS TRANSMEMBRANE CONDUCTANCE REGULATOR | VERTEX PHARMACEUTICALS, SAN DIEGO | 2023-11-23 | — | — | US | disclosed |
| US-20230373935-A1 | MODULATORS OF CYSTIC FIBROSIS TRANSMEMBRANE CONDUCTANCE REGULATOR | VERTEX PHARMACEUTICALS, SAN DIEGO | 2023-11-23 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230373935-A1 | MODULATORS OF CYSTIC FIBROSIS TRANSMEMBRANE CONDUCTANCE REGULATOR | CFTR, SCNN1G, SCNN1B | GPR119 612/4885HTR1A 4018/4885HTR7 3833/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.